



### Company Overview

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories.

### Emmaus Life Sciences Reports Delayed Filing of Annual Report

Apr 15 2024, 4:07 PM EDT

### Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico

Feb 2 2024, 10:00 AM EST

### Emmaus Life Sciences Reports Q3 2023 Financial Results

Nov 14 2023, 9:30 AM EST

### Stock Overview

Symbol	EMMA
Exchange	OTCQB
Market Cap	6.1m
Last Price	\$0.11
52-Week Range	\$0.05 - \$0.35

04/16/2024 12:31 PM EDT

### Management Team

#### Willis C. Lee, MS

Co-President, Chief Operating Officer, Director

#### George Sekulich

Co-President, Chief Commercial Officer, Director

#### Yasushi Nagasaki, CPA

Chief Financial Officer

#### Charles W. Stark, Pharm.D.

Senior Vice President of Medical Affairs, Clinical, Regulatory

#### Dale E. Short, JD

Legal Consultant and Corporate Secretary

### Emmaus Life Sciences, Inc.

21250 Hawthorne Blvd.  
Suite 800  
Torrance, CA 90503

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.